Nkarta(NKTX) - 2025 Q4 - Annual Results

Exhibit 99.1 Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights SOUTH SAN FRANCISCO, Calif., March 25, 2026 -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today reported financial results for the fourth quarter and year ended December 31, 2025. "2025 was a year of strategic importance for Nkarta as we onboarded a clinical team with deep autoimmune experience ...